~~<i id='DD6642736E'><strike id='DD6642736E'><tt id='DD6642736E'><pre id='DD6642736E'></pre></tt></strike></i>~~

Home» knowledge» fashion

fashion

author：focus 2025-09-30 01:44:28 Page View：99877

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Maisha Meds is a PBM, but don't call it that
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Hospitals look to new technology to keep health care workers safe

AdobeOnedayinearly2020,justweeksbeforePhiladelphiaenteredlockdown,ThomasJeffersonUniversity’spublics

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

FDA sets aggressive timeline for overhauling inspection procedures

AdobeWASHINGTON—FoodandDrugAdministrationofficialshopetofinishthisyearamassiveoverhaulofthewaytheage